Tracers / [177Lu]Lu-LuPSMA-617
[177Lu]Lu-LuPSMA-617
Also written as [Lu-177]LuPSMA-617
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- approved
- Syntheses indexed
- 8
What it is
- Compound class
- PSMA-617, urea-based PSMA-targeting ligand (Glu-urea-Lys pharmacophore) labeled with Lutetium-177
- Target / mechanism
- Targets prostate-specific membrane antigen (PSMA) PMID 36288537
- Clinical application
- Radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC) PMID 36288537
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | >95% | PSMA-617 ligand MedKoo Biosciences | 40397137 2025 Eur J Nucl Med Mol Imaging The PSMA-617 ligand (MedKoo Biosciences) was prepared as described by Stenberg et al. |
| Manual synthesis | — | — | ≥99% | ≥99% | PSMA-617 ABX | 37889298 2024 Eur J Nucl Med Mol Imaging The administered [177Lu]Lu-PSMA-617 was synthesized in accordance with standard procedures as described by Kratochwil et al. [30]. — Yield and purity of the radio tracer were ≥99%. |
| — | — | — | — | — | PSMA-617 | 36288537 2022 Oncologist |
| Manual synthesis | — | — | — | — | PSMA-617 | 35807385 2022 Molecules For the radiolabeling of [177Lu]Lu-PSMA-I&T, a manual synthesis was used. |
| Scintomics GRP / GRP-3V Scintomics | vendor cassette | none | >90 % | 92 % | PSMA-617 ABX | 27090254 2016 EJNMMI Res Both kinds of synthesis was carried out with a Scintomics GRP synthesizer, sterile single use cassettes and the standard synthesis sequences for 68Ga-peptides respective therapeutic peptides. — The labelling to 177Lu-PSMA-617 was quantitative, there for the yield was >90 % |
| — | — | — | — | — | — | 41642049 2026 Clin Nucl Med |
| — | — | — | — | — | — | 39978808 2025 J Nucl Med |
| — | — | — | — | — | PSMA-617 | 37670407 2023 J Med Chem |
Need this precursor?We can point you to suppliers for [177Lu]Lu-LuPSMA-617, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 36288537: 'This has ultimately led to the approval of this therapy by the US Food and Drug Administration (FDA) on March 23 2022.'.